Post-COVID-19 Fungal Infection in the Aged Population
Vivek P. Chavda,
Toshika Mishra,
Sathvika Kamaraj,
Swati Punetha,
Oishani Sengupta,
Yash Joshi,
Suneetha Vuppu,
Dixa Vaghela,
Lalitkumar Vora
Affiliations
Vivek P. Chavda
Department of Pharmaceutics and Pharmaceutical Technology, L.M. College of Pharmacy, Ahmedabad 380009, Gujarat, India
Toshika Mishra
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Sathvika Kamaraj
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Swati Punetha
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Oishani Sengupta
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Yash Joshi
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Suneetha Vuppu
Science, Innovation, and Society Research Lab. 115, Department of Biotechnology, Hexagon (SMV), Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India
Dixa Vaghela
Pharmacy Section, L.M. College of Pharmacy, Ahmedabad 380009, Gujarat, India
Lalitkumar Vora
School of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UK
Coronavirus disease 2019 (COVID-19) infection is currently a great cause of concern for the healthcare sector around the globe. SARS-CoV-2 is an RNA virus that causes a serious infection that is associated with numerous adverse effects and multiple complications associated with different organs and systems during its pathogenic cycle in humans. Individuals affected by COVID-19, especially elderly populations and immunocompromised people, are greatly vulnerable to opportunistic fungal pathogens. Aspergillosis, invasive candidiasis, and mucormycosis are widespread fungal coinfections in COVID-19 patients. Other fungal infections that are rare but are exhibiting increased incidence in the current scenario include infections caused by Pneumocystis jirovecii, Histoplasma sp., Cryptococcus sp., etc. By producing virulent spores, these pathogens increase the severity of the disease and increase the morbidity and fatality rates in COVID-19 patients globally. These infections generally occur in patients recovering from COVID-19 infection, resulting in rehospitalization. Older and immunocompromised individuals are at higher risk of developing opportunistic fungal infections. This review focuses on understanding the opportunistic fungal infections prevalent in COVID-19 patients, especially elderly people. We have also highlighted the important preventive methods, diagnostic approaches, and prophylactic measures for fungal infections.